Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer

Goto, Taichiro; Maeshima, Arafumi; Oyamada, Yoshitaka; Kato, Ryuichi

doi:10.1007/s10147-013-0566-1

Cited by 40 publications

(39 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both COPD and IPF have been linked to lung cancer and whereas studies indicate that COPD is a risk factor for lung cancer and that COPD patients might have underlying lung cancer [37,38], results are somewhat more contradictory for IPF [39]. Still, IPF have been described as a prognostic factor in NSCLC [40] and in a study by Nagai et al, lung cancer was found to be present in one-third of the IPF patients analyzed [41]. We speculate that it might be possible that the two (10%) false positive lung cancer patients from the diagnostic decision tree (i.e., one IPF patient and one COPD patient), may have underlying undiagnosed lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer

et al. 2014

View full text Add to dashboard Cite

Extracellular matrix (ECM) proteins, such as collagen type I and elastin, and intermediate filament (IMF) proteins, such as vimentin are modified and dysregulated as part of the malignant changes leading to disruption of tissue homeostasis. Noninvasive biomarkers that reflect such changes may have a great potential for cancer. Levels of matrix metalloproteinase (MMP) generated fragments of type I collagen (C1M), of elastin (ELM), and of citrullinated vimentin (VICM) were measured in serum from patients with lung cancer (n = 40), gastrointestinal cancer (n = 25), prostate cancer (n = 14), malignant melanoma (n = 7), chronic obstructive pulmonary disease (COPD) (n = 13), and idiopathic pulmonary fibrosis (IPF) (n = 10), as well as in age-matched controls (n = 33). The area under the receiver operating characteristics (AUROC) was calculated and a diagnostic decision tree generated from specific cutoff values. C1M and VICM were significantly elevated in lung cancer patients as compared with healthy controls (AUROC = 0.98, P < 0.0001) and other cancers (AUROC = 0.83 P < 0.0001). A trend was detected when comparing lung cancer with COPD+IPF. No difference could be seen for ELM. Interestingly, C1M and VICM were able to identify patients with lung cancer with a positive predictive value of 0.9 and an odds ratio of 40 (95% CI = 8.7–186, P < 0.0001). Biomarkers specifically reflecting degradation of collagen type I and citrullinated vimentin are applicable for lung cancer patients. Our data indicate that biomarkers reflecting ECM and IMF protein dysregulation are highly applicable in the lung cancer setting. We speculate that these markers may aid in diagnosing and characterizing patients with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The adjusted HR for death for lung cancer versus no lung cancer was reported as 2.4 (95% CI 1.4-4.3; p=0.002) [89]. In a retrospective Japanese single-centre study, histopathologically confirmed IPF was identified as a significant negative prognostic factor for post-operative mortality and long-term survival in 387 primary lung cancer patients treated by surgical resection [98].…”

Section: Lung Cancermentioning

confidence: 99%

“…In patients who received surgical treatment for lung cancer, post-operative mortality (e.g. 30-day, 90-day, in-hospital) tended to be low (0 deaths [95,96], 4% [96,97], 5% [98], 7% [97], 8% [98,99], 12% [93,98]), although a small database review from China reported a post-operative mortality rate of 33.3% (two of six patients) [84]. Median survival from IPF diagnosis was between 7 (95% CI 2.51-11.49) and 26.9 months (95% CI 14.67-39.05) [84,89].…”

Section: Lung Cancermentioning

confidence: 99%

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

et al. 2015

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in patients over 60 years old who may have comorbidities. The prevalence and impact of comorbidities on the clinical course of IPF is unclear.This systematic literature review examined the prevalence of comorbidities and mortality associated with comorbidities in IPF patients. Relevant observational studies published in English from January 1990 to January 2015 identified via MEDLINE and EMBASE were included; bibliographies of articles were also searched.Among the 126 studies included, prevalence of pulmonary hypertension (PH) was 3-86%, 6-91% for obstructive sleep apnoea, 3-48% for lung cancer and 6-67% for chronic obstructive pulmonary disease (COPD). Nonrespiratory comorbidities included ischaemic heart disease (IHD) (3-68%) and gastrooesophageal reflux (GER) (0-94%). Mortality was highest among patients with IPF and lung cancer. Most studies assessed relatively small samples of patients with IPF.PH, COPD, lung cancer, GER and IHD are significant comorbidities; differences in IPF severity, case definitions and patient characteristics limited the comparability of findings. The identification and prompt treatment of comorbidities may have a clinically significant impact on overall outcome that is meaningful for patients with IPF. @ERSpublications Identification and prompt treatment of comorbidities has a clinically significant impact on outcome for IPF patients

show abstract

“…70-11.48, p<0.001) [28][29][30]. Moreover, idiopathic pulmonary fibrosis has been described as an independent risk factor for postoperative mortality and poor long-term survival, especially in patients with stage I/II NSCLC [31]. In patients with underlying ILD, lung cancers are mostly squamous-cell carcinomas and located at the periphery of the lung [32,33].…”

Section: Interstitial Lung Diseasesmentioning

confidence: 99%

Comorbidities in the management of patients with lung cancer

Leduc

Antoni²,

Charloux³

et al. 2017

Eur Respir J

104

View full text Add to dashboard Cite

Lung cancer represents a major public health issue worldwide. Unfortunately, more than half of them are diagnosed at an advanced stage. Moreover, even if diagnosed early, diagnosis procedures and treatment can be difficult due to the frequent comorbidities observed in these patients. Some of these comorbidities have a common major risk factor, smoking, whereas others are unrelated to smoking but frequently observed in the general population. These comorbidities must be carefully assessed before any diagnostic and/or therapeutic decisions are made regarding the lung cancer. For example, in a patient with severe emphysema or with diffuse lung fibrosis, transthoracic needle biopsy can be contraindicated, meaning that in some instances a precise diagnosis cannot be obtained; in a patient with chronic obstructive pulmonary disease, surgery may be impossible or should be preceded by intensive rehabilitation; patients with interstitial lung disease are at risk of radiation pneumonitis and should not receive drugs which can worsen the respiratory insufficiency. Patients who belong to what are called "special populations", elderly or HIV infected, should be treated specifically, especially regarding systemic treatment. Last but not least, psychosocial factors are of great importance and can vary from one country to another according to health insurance coverage.

show abstract

Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer

Abstract: Histopathological evidence of IPF was a risk factor for postoperative mortality and poor long-term survival, especially in patients with stage I/II non-small cell lung cancer, with postoperative respiratory failure representing the major cause of death.

Cited by 40 publications

References 27 publications

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

Comorbidities in the management of patients with lung cancer

Contact Info

Product

Resources

About